semaglutide shortage update fda On February 21, 2025, the FDA announced that semaglutide, the active ingredient in Compounded GLP-1 Medications: What’s Changing

Judicial Panel on Multidistrict Litigation created a streamlined federal MDL for GLP-1 NAION lawsuits, centralizing the claims in the Eastern District of Pennsylvania before U.S

Sleep improvements typically appear within 2-4 weeks, while body composition and performance changes develop over 2-3 months, with continued optimization through 6 months

In fact, some trials observed slight improvements in metabolic markers, likely secondary to fat loss rather than direct peptide effects

GLP-1 Case Study Name: Richard J., a 58-year-old male Medical History: Type 2 Diabetes Mellitus (diagnosed 7 years ago) Obesity (BMI 35 kg/m) Hypertension (well-controlled on an ACE inhibitor) Mild diabetic retinopathy Current Medications: Metformin 1000 mg twice daily, glimepiride 2 mg once daily, and lisinopril 20 mg once daily Clinical Presentation Richard presents a routine follow-up

You do not pick one number and stay there

Subcutaneous injection delivers the peptide directly into systemic circulation, bypassing first-pass metabolism